Resveratroloside
(Synonyms: 白藜芦醇-4'-O-葡萄糖苷,trans-Resveratrol 4'-O-β-D-glucopyranoside) 目录号 : GC61242
Resveratroloside是一种α-glucosidase的竞争新抑制剂，能调节血糖水平。Resveratroloside具有心脏保护作用。
Cas No.:38963-95-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Resveratroloside is a competitive inhibitior of α-glucosidase with an IC50 of 22.9 μM. Resveratroloside has the ability to regulate PBG (postprandial blood glucose) levels. Resveratroloside exhibits cardioprotective effect[1][2].
[1]. Zhao X, et al. Resveratroloside Alleviates Postprandial Hyperglycemia in Diabetic Mice by Competitively Inhibiting α-Glucosidase. J Agric Food Chem. 2019 Mar 13;67(10):2886-2893. [2]. Naumenko SE, et al. Cardioprotective effect of resveratrol and resveratroloside. Cardiovasc Hematol Agents Med Chem. 2013 Sep;11(3):207-10.
| Cas No. | 38963-95-0 | SDF | |
| 别名 | 白藜芦醇-4'-O-葡萄糖苷,trans-Resveratrol 4'-O-β-D-glucopyranoside | ||
| Canonical SMILES | OC1=CC(O)=CC(/C=C/C(C=C2)=CC=C2O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)CO)=C1 | ||
| 分子式 | C20H22O8 | 分子量 | 390.38 |
| 溶解度 | 储存条件 | Store at -20°C | |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5616 mL | 12.808 mL | 25.6161 mL |
| 5 mM | 0.5123 mL | 2.5616 mL | 5.1232 mL |
| 10 mM | 0.2562 mL | 1.2808 mL | 2.5616 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Resveratroloside Alleviates Postprandial Hyperglycemia in Diabetic Mice by Competitively Inhibiting α-Glucosidase
J Agric Food Chem 2019 Mar 13;67(10):2886-2893.PMID:30785285DOI:10.1021/acs.jafc.9b00455.
The regulation of postprandial blood glucose (PBG) levels is an effective therapeutic method to treat diabetes and prevent diabetes-related complications. Resveratroloside is a monoglucosylated form of stilbene that is present in red wine, grapes, and several traditional medicinal plants. In our study, the effect of Resveratroloside on reducing PBG was studied in vitro and in vivo. In comparison to the starch treatment alone, the oral administration of resveratroloside-starch complexes significantly inhibited the PBG increase in a dose-dependent pattern in normal and diabetic mice. The PBG level treated with resveratrol (30 mg/kg) was not lower than that of Resveratroloside. Further analyses demonstrated that Resveratroloside strongly and effectively inhibited α-glucosidase, with an 50% inhibitory concentration value of 22.9 ± 0.17 μM, and its inhibition was significantly stronger than those of acarbose and resveratrol (264 ± 3.27 and 108 ± 2.13 μM). Moreover, a competitive inhibition mechanism of Resveratroloside on α-glucosidase was determined by enzyme kinetic assays and molecular docking experiments. The molecular docking of Resveratroloside with α-glucosidase demostrated the competitive inhibitory effect of Resveratroloside, which occupies the catalytic site and forms strong hydrogen bonds with the residues of α-glucosidase. Resveratrol was also determined to be a competitive inhibition mechanism on α-glucosidase by enzyme kinetic assays and molecular docking experiments. This study suggested that Resveratroloside had the ability to regulate PBG levels and can be considered a potential agent for the treatment of diabetes mellitus.
Cardioprotective effect of resveratrol and Resveratroloside
Cardiovasc Hematol Agents Med Chem 2013 Sep;11(3):207-10.PMID:23547903DOI:10.2174/187152571103140120103302.
Cardioprotective effect of resveratrol and Resveratroloside was determined in ischemia-reperfusion experiments on rats. It was found that single intraperitoneal administration of any compound (10 mg/kg) followed by 30-min ischemia and 120-min reperfusion resulted in statistically significant decrease of myocardial infarct area (55.0±4.0% for control group; 40.7±4.4% for the group 1 received resveratrol; 41.6±4.8% for the group 2 received Resveratroloside). The cardioprotective effect of Resveratroloside was detected for the first time.
Glycyrrhetinic acid and E.Resveratroloside act as potential plant derived compounds against dopamine receptor D3 for Parkinson's disease: a pharmacoinformatics study
Drug Des Devel Ther 2014 Dec 18;9:187-98.PMID:25565772DOI:10.2147/DDDT.S72794.
Parkinson's disease (PD) is caused by loss in nigrostriatal dopaminergic neurons and is ranked as the second most common neurodegenerative disorder. Dopamine receptor D3 is considered as a potential target in drug development against PD because of its lesser side effects and higher degree of neuro-protection. One of the prominent therapies currently available for PD is the use of dopamine agonists which mimic the natural action of dopamine in the brain and stimulate dopamine receptors directly. Unfortunately, use of these pharmacological therapies such as bromocriptine, apomorphine, and ropinirole provides only temporary relief of the disease symptoms and is frequently linked with insomnia, anxiety, depression, and agitation. Thus, there is a need for an alternative treatment that not only hinders neurodegeneration, but also has few or no side effects. Since the past decade, much attention has been given to exploitation of phytochemicals and their use in alternative medicine research. This is because plants are a cheap, indispensable, and never ending resource of active compounds that are beneficial against various diseases. In the current study, 40 active phytochemicals against PD were selected through literature survey. These ligands were docked with dopamine receptor D3 using AutoDock and AutoDockVina. Binding energies were compared to docking results of drugs approved by the US Food and Drug Administration against PD. The compounds were further analyzed for their absorption, distribution, metabolism, and excretion-toxicity profile. From the study it is concluded that glycyrrhetinic acid and E.Resveratroloside are potent compounds having high binding energies which should be considered as potential lead compounds for drug development against PD.
From bench to counter: Discovery and validation of a peony extract as tyrosinase inhibiting cosmeceutical
Eur J Med Chem 2019 Dec 15;184:111738.PMID:31655335DOI:10.1016/j.ejmech.2019.111738.
The anti-melanogenic principle of peony (Paeonia officinalis subsp. officinalis) seeds was elucidated via activity-guided isolation. Resveratroloside (trans-resveratrol-4'-O-beta-d-glucopyranoside) was found to be the main metabolite of P. officinalis subsp. officinalis seeds and its tyrosinase inhibiting activity was confirmed via an enzymatic assay. Furthermore, the in vitro activity and the therapeutic window were studied employing the murine melanoma cell line B16F10. The results from the conducted stability assay and the high content of Resveratroloside in the seeds (i.e. 10.4% dw) motivated us to push the extract forward to an in vivo tolerance assay. A clinical study with forty Caucasian participants proofed a good skin-tolerance with high moisture effect and reduction of pores.
Analysis and functionality of major polyphenolic components of Polygonum cuspidatum (itadori)
J Nutr Sci Vitaminol (Tokyo) 2012;58(4):278-86.PMID:23132312DOI:10.3177/jnsv.58.278.
Polygonum cuspidatum has been broadly utilized as a herbal medicine in Asia, but the outline of the polyphenol compounds in the plant has not been characterized well. In the present study, the major polyphenolic components were isolated from the roots of P. cuspidatum, and identified as resveratrol and its glucosides, Resveratroloside and polydatin. On the other hand, chlorogenic acid was found to be one of the polyphenolic components in the leaves and stems of the plant. Next, we elucidated that resveratrol derivatives and chlorogenic acid exhibit α-glucosidase inhibitory activities, and Resveratroloside exhibits the same inhibitory activity as quercetin does. Furthermore, DPPH radical scavenging activities of antioxidants including resveratrol derivatives and chlorogenic acid derivatives were examined by initial rate analyses of their reactions. Subsequently, it was revealed that resveratrol derivatives have slow-acting effects on the radical scavenging activity and that chlorogenic acid derivatives exhibit very fast-acting effects.